EP. 1: Presentation: Benefits and Limitations of RWE: Lessons From EGFR Mutation-Positive NSCLC
Dr. Lyudmila Bazhenova presents a recently published article by Nazha B, et al., “Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer.”
EP. 2: EGFR-Mutant NSCLC: Addressing Gaps When Collecting Data
Federico Albrecht, MD, reacts to limitations regarding the designs and outcomes of randomized controlled trials in EGFR-mutant non–small cell lung cancer and describes his interest in collecting real-world data.
EP. 3: Experts in Treating EGFR-Positive NSCLC Compare Randomized Trials and Real-World Studies
Lyudmila A. Bazhenova, MD, and Federico Albrecht, MD, spoke about treating patients with EGFR-positive non–small cell lung cancer through randomized clinical trials and real-world studies.
EP. 4: EGFR-Mutant NSCLC: Incorporating RWE Into Treatment Decisions
Drs Lyudmila Bazhenova and Federico Albrecht comment on the pros and cons of real-world evidence to guide treatment decisions for patients with EGFR-mutant non–small cell lung cancer.
EP. 5: Referring to Real-World Evidence When Managing EGFR-Mutant NSCLC
Information provided by real-world data that is noted to be the most valuable to thoracic oncologists and others who manage patients with EGFR-mutant non–small cell lung cancer.
EP. 6: Using Various Sources of Information to Guide Management of EGFR-Mutated NSCLC
Recommendations for how to best treat patients with EGFR-mutated non–small cell lung cancer when there are discrepancies between clinical trial data and real-world evidence.
EP. 7: Increasing Rates of Real-World Studies in EGFR-Mutated NSCLC